Elma Meershoek-Klein Kranenbarg

Head Clinical Research Center

Leiden University Medical Center

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Cancer Biology Cancer Biology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Elma Meershoek-Klein Kranenbarg is the Head of the Clinical Research Center at Leiden University Medical Center in the Netherlands. Her research focuses on cancer treatment strategies, including the tumor-stroma ratio in rectal carcinoma and chemotherapy compliance in gastric cancer. She has contributed to various studies on breast cancer, particularly concerning endocrine therapy and patient selection based on risk factors. Her recent publications reflect her commitment to advancing therapeutic approaches in oncology.

Articles (9)

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

Assistant Professor - Head, Leiden Genome Technology Center

Leiden University Medical Center

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Elma Meershoek-Klein Kranenbarg

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

The tumour–stroma ratio as predictive aid towards a biopsy‐based treatment strategy in rectal carcinoma

Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Longitudinal Serum Protein Analysis of Women with a High Risk of Developing Breast Cancer Reveals Large Interpatient Versus Small Intrapatient Variations: First Results from the TESTBREAST Study

Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women With Estrogen Receptor–Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer

Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer

Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial

Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy

Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

Collaborators (5)

Geke Hospers

Hein Putter

Jakob de Vries

Hanno Pijl

Susan Kloet

Make your next move.